Sign in

You're signed outSign in or to get full access.

Chad Street

About Chad C. Street

Chad C. Street, DMD, MD, age 53, is an independent director of Community Trust Bancorp, Inc. (CTBI), elected to the Board in 2021; he has served on Community Trust Bank, Inc. (CTB)’s Board since 2017 . He holds a DMD from the University of Kentucky (1996) and completed a combined DMD/MD Oral & Maxillofacial Surgical residency at UK Chandler Medical Center (completed June 2003); he is in private practice in Pikeville, KY, and owns East Kentucky Oral & Maxillofacial Surgery, PSC, and Street Investments, LLC . The Board classifies him as independent under Nasdaq standards; CTBI’s Board held eight meetings in 2024 and each director met the 75% attendance threshold .

Past Roles

OrganizationRoleTenureCommittees/Impact
East Kentucky Oral & Maxillofacial Surgery, PSCSole Owner and SurgeonSince 2006 (after 3-year associateship)Practice management and financial oversight
University of Kentucky Medical CenterStaff privileges; voluntary faculty (medical school and surgical departments)Ongoing (dates not specified)Clinical privileges and voluntary teaching
Pikeville Medical CenterStaff privilegesOngoing (dates not specified)Inpatient/outpatient surgical privileges
Kentucky Mountain Dental SocietyPast President (three terms)Not specifiedDental community leadership
CTB BoardDirectorSince 2017Member, CTB Loan Committee

External Roles

OrganizationRoleScope
University of Pikeville (UPIKE) Osteopathic School of MedicineVoluntary faculty preceptorAcademic mentoring/preceptorship
University of Kentucky Medical SchoolVoluntary facultyAcademic contributions
University of Kentucky Chandler Medical CenterTraining completion; ongoing consultsOral & maxillofacial surgery training and consultations

Board Governance

  • Independence: The Board determined Dr. Street is independent under Nasdaq Rule 5605; nine of ten CTBI directors are independent .
  • Committee assignments (CTBI Board): Executive Committee; Audit and Asset Quality Committee; Risk and Compliance Committee; Nominating and Corporate Governance Committee; CTB Loan Committee .
  • Attendance: Board held eight meetings in 2024; each director attended at least 75% of Board and committee meetings; Board held four executive sessions of non-management directors .
  • Lead Independent Director: Eugenia “Crit” Luallen serves as Vice Chairman and Lead Independent Director .
  • Committee activity levels (2024):
    • Audit and Asset Quality Committee: 13 meetings; all members independent; audit financial expert designated (Farris) .
    • Compensation Committee: 2 meetings; all members independent .
    • Nominating & Corporate Governance: 1 meeting; all members independent .
    • Risk & Compliance: 4 meetings; all members independent .
CommitteeRole/Status2024 Meetings
Executive CommitteeMemberNot disclosed by count
Audit & Asset QualityMember (independent)13
Risk & ComplianceMember (independent)4
Nominating & Corporate GovernanceMember (independent)1
CTB Loan CommitteeMemberMonthly participation up to $300/month noted for CTB Loan Committee service (structure described)

Governance policies

  • Hedging/pledging: Directors and executive officers are prohibited from hedging and from pledging a “significant” amount of CTBI equity (defined as the lesser of 1% of outstanding equity or 50% of their holdings) .
  • Related-party transaction oversight: Compensation Committee reviews and approves related-party transactions; ordinary-course credit transactions for directors occur on market terms without unfavorable features per Board opinion .

Fixed Compensation

2024 Director Compensation (structure and Dr. Street’s fees)

  • Structure: $16,250 per quarter retainer; committee meeting fees ($600 when held the day prior to quarterly Board meetings; $100 by telephone for special meetings; $300 for other committee meetings on separate days); incremental stipends for chairs/lead director; no stock awards or options to directors in 2024 .
  • Fees paid: Dr. Street received $72,400 total fees for 2024 .
ComponentAmount/Detail
Quarterly director retainer$16,250 per quarter
Committee meeting fees$600 (day prior to regular Board); $100 (special by phone); $300 (other committee meetings on separate days)
Chair stipends (quarterly)Audit Chair $3,125; Compensation Chair $2,125; Risk Chair $1,875; Nominating Chair $1,875; Corporate Retirement Chair $1,250
Lead Independent Director stipend$2,500 (2024)
Options/Stock grants to directorsNone in 2024
Dr. Street – 2024 total fees$72,400

2025 Director Compensation (approved changes; subject to equity plan approval)

  • Mix: Annual compensation increased by $10,000 and shifted to $55,000 cash + $20,000 equity (stock award), contingent on shareholder approval of the Amended and Restated 2025 Stock Ownership Incentive Plan .
  • Committee/lead director fees (2025): Lead Director $20,000; Joint Audit Chair $12,500; Compensation Chair $8,500; Risk Chair $7,500; Nominating Chair $7,500; Corporate Retirement Chair $5,000; per-meeting fees: Audit $750; Risk $750; Compensation $500; Nominating $500; Corporate Retirement $500 .
2025 Role/ComponentAmount
Base director cash retainer$55,000
Director equity (stock award)$20,000 (subject to plan approval)
Lead Independent Director stipend$20,000
Audit & Asset Quality Chair$12,500
Compensation Chair$8,500
Risk & Compliance Chair$7,500
Nominating & Corporate Governance Chair$7,500
Corporate Retirement & Employee Benefit Chair$5,000
Per-meeting fees (Audit/Risk)$750
Per-meeting fees (Comp/NCG/Retirement)$500

Performance Compensation

Director equity under 2025 Stock Ownership Incentive Plan (pending shareholder approval)

  • Purpose: Enable stock awards to directors; broaden eligible participants to include Board members .
  • Authorized shares: 550,000 shares; equity plan has no repricing without shareholder approval .
  • Director stock awards: Unrestricted stock awards may be granted, capped at 5% of total plan shares; restricted stock must have minimum one-year restriction; stock options/SARs minimum one-year to vest .
  • Change-in-control protection: Double-trigger acceleration for options/SARs/restricted stock; performance units (for executives) accelerate per defined formula .
  • Recoupment: All awards subject to CTBI’s clawback policy and applicable listing standards .
Plan FeatureDetail
Eligible participantsFull-time employees; if restatement approved, Board members eligible
Authorized shares550,000
Director stock awardsUnrestricted stock awards allowed; aggregate cap 5% of plan shares
Restricted stock minimum restriction≥1 year; performance or service-based
Options/SARsGrant price ≥ fair market value; vest ≥1 year
No repricingWithout shareholder approval
Change-in-controlDouble-trigger acceleration for equity; formula for performance units
Recoupment/clawbackSubject to CTBI policies and listing standards

Note: CTBI did not grant equity to directors in 2024; equity awards to directors begin in 2025 contingent on shareholder approval of the plan .

Other Directorships & Interlocks

EntityTypeRoleNotes
Community Trust Bank, Inc. (CTB)SubsidiaryDirector; CTB Loan Committee memberContinues service; meeting fee structure disclosed
CTIC (Trust subsidiary)SubsidiaryNot specifically disclosed for Dr. StreetNot listed for Dr. Street
  • No other public company directorships are disclosed for Dr. Street .
  • Related-party transactions oversight exists; ordinary-course director banking relationships occur on market terms (no unfavorable features per Board’s opinion) .

Expertise & Qualifications

  • Clinical and medical leadership: Oral & maxillofacial surgeon with nearly 20 years of practice and hospital privileges; voluntary faculty roles at UK and UPIKE .
  • Business/financial management: Sole owner/operator with extensive financial and practice management experience; ownership of a real estate management company (Street Investments, LLC) .
  • Community leadership: Past President (three terms) of the Kentucky Mountain Dental Society .

Equity Ownership

HolderShares Beneficially OwnedNotes% of Outstanding Shares
Chad C. Street6,100Includes 1,100 shares held by his wife over which he has no voting or investment power 0.034% (6,100 / 18,101,765)
  • Hedging and significant pledging of CTBI stock by directors is prohibited under Insider Trading Policy .

Governance Assessment

  • Strengths:

    • Independent director with multi-committee engagement (Executive, Audit, Risk, Nominating), signaling strong Board participation and oversight breadth .
    • Board policy prohibits hedging and significant pledging, supporting ownership alignment and reducing risk .
    • 2025 shift to include director equity improves alignment with shareholders; no equity to directors in 2024 mitigated dilution concerns, but added equity enhances skin-in-the-game going forward .
    • Board held executive sessions, and Lead Independent Director structure provides counterbalance to combined CEO/Chair roles .
  • Potential risks/monitoring points:

    • Combined CEO/Chair role can concentrate power; mitigated by an active Lead Independent Director and majority independent board .
    • Director-related banking transactions occur in the ordinary course; ongoing committee oversight of related-party transactions reduces conflict risk (note policy process) .
    • No specific red flags disclosed for Dr. Street (no late Section 16 filings for him; no disclosed related-party transactions involving his entities), but vigilance on any future CTBI credit exposure to his private businesses remains prudent under the stated policy framework .